Epithelial membrane protein 2 (EMP2)，是growth arrest specific-3/peripheral myelin protein-22(GAS3/PMP22)家族的成員，以tetraspan形式存在於細胞膜上之蛋白質。在過去研究證明EMP 在子宮內膜是致腫瘤基因，但B-淋巴細胞卻是個腫瘤抑制基因。然而到目前為止在不同的癌症細胞EMP2對細胞影響之確切的分子機制尚未清楚。在初步的研究裡，我們觀察到在膀胱癌細胞裡EMP2的表現亮會隨著級數的增加而下降。在這個實驗，首先我們將EMP2基因全長接進pEGFP-N3載體，當作過度表現的工具。然後我們將J82細胞過度表現EMP2，另外經由shEMP2抑制RT4細胞的EMP2的表現，然後觀察EMP2對於膀胱癌細胞的增生、細胞週期、細胞凋亡和細胞轉移的影響。研究結果發現EMP2會導致細胞週期堆積在G2/M期，降低J82細胞增生能力。另一方面抑制RT4細胞EMP2表現會增加細胞的增生能力。此外EMP2也會影響J82和RT4細胞的遷移能力。

Epithelial membrane protein 2(EMP2), a growth arrest specific-3/peripheral myelin protein-22(GAS3/PMP22) family member, is a tetraspan protein. In prior study identified EMP2 in endometrial cancer was an oncogene, but in B-cell lymphoma was a tumor suppressor gene. The effects of EMP2 on various cancer cell lines precise molecular mechanisms are not clear until now. We observed EMP2 was down-regulated following the progressive grades of bladder cancer cell lines. So, we clone the EMP2 full-length cDNA into the pEGFP-N3 vector as an tool. Then, we overexpressed EMP2 in bladder cancer cell line J82 cells and knockdown EMP2 by shEMP2 in bladder cancer cell line RT4 cells in order to examine its effects on functions of cells like proliferation, cycle , apoptosis and metastasis. Conclusion, we can get cell proliferation of EMP2-overexprssed cells were decreased through arresting G2/M phase of cell cycle. On the other hand, knockdown of EMP2 in RT4 cells increased cell proliferation. Moreover, the ability of migration were decreased by EMP2 in both J82 and RT4 cells.

English abstract------------------------------------------------------------------- I
中文摘要---------------------------------------------------------------------------- II
英文縮寫表------------------------------------------------------------------------- III
目錄---------------------------------------------------------------------------------- 1
一、 緒論------------------------------------------------------------------------- 2
二、 材料方法------------------------------------------------------------------ 9
三、 結果------------------------------------------------------------------------- 24
四、 討論------------------------------------------------------------------------- 41
五、 參考文獻------------------------------------------------------------------ 44

1. Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 1985;45(11 Pt 2):5895-9.

2. Pan BJ, Hong YJ, Chang GC, Wang MT, Cinkotai FF, Ko YC. Excess cancer mortality among children and adolescents in residential districts polluted by petrochemical manufacturing plants in Taiwan. J Toxicol Environ Health 1994;43(1):117-29.

3. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130(6):1083-6.

4. Li C, Teng RH, Tsai YC, et al. H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br J Cancer 2005;92(1):80-8.

5. Kang CH, Yu TJ, Hsieh HH, et al. The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98(8):1620-6.

6. Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Shiue YL. Synchronous bilateral primary transitional cell carcinoma of the upper urinary tracts: ten patients with more than five years of follow-up. Urology 2004;63(2):380-2.

7. Heinzer H, Huland E, Monk M, Huland H. Distribution of 486P 3/12 antigen, ABO(H) blood group antigen and T antigen in cystectomy specimens from patients with stage T2 transitional cell carcinoma of the bladder. J Urol 1992;148(3):802-5.

8. Lee CC, Yamamoto S, Morimura K, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer 1997;79(4):780-9.

9. Witjes JA, Umbas R, Debruyne FM, Schalken JA. Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer. J Urol 1995;154(6):2185-9.

10. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150(1):60-4.

11. Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res Mol Biol 2000;64:97-129.

12. Taylor V, Suter U. Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene 1996;175(1-2):115-20.

13. Wang CX, Wadehra M, Fisk BC, Goodglick L, Braun J. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood 2001;97(12):3890-5.

14. Wilson HL, Wilson SA, Surprenant A, North RA. Epithelial membrane proteins induce membrane blebbing and interact with the P2X7 receptor C terminus. J Biol Chem 2002;277(37):34017-23.

15. Wadehra M, Su H, Gordon LK, Goodglick L, Braun J. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin Immunol 2003;107(2):129-36.

16. Wadehra M, Goodglick L, Braun J. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell 2004;15(5):2073-83.

17. Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol 2003;74(2):106-12.

18. Wadehra M, Forbes A, Pushkarna N, et al. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol 2005;287(2):336-45.

19. Wadehra M, Natarajan S, Seligson DB, et al. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 2006;107(1):90-8.

20. Wadehra M, Mainigi M, Morales SA, et al. Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol 2008;6:15.

21. Morales SA, Mareninov S, Wadehra M, et al. Epithelial Membrane Protein 2 (EMP2) Controls Collagen Gel Contraction in ARPE-19 Cells by Modulating FAK Activation. Invest Ophthalmol Vis Sci 2008.

22. Shimazaki K, Lepin EJ, Wei B, et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 2008;14(22):7367-77.

23. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268(5212):884-6.

24. Jankowski SA, Mitchell DS, Smith SH, Trent JM, Meltzer PS. SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins. Oncogene 1994;9(4):1205-11.

25. Marken JS, Schieven GL, Hellstrom I, Hellstrom KE, Aruffo A. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A 1992;89(8):3503-7.

26. Szala S, Froehlich M, Scollon M, et al. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A 1990;87(9):3542-6.

27. Doree M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994;8(14):1114-21.

28. Lewin B. Driving the cell cycle: M phase kinase, its partners, and substrates. Cell 1990;61(5):743-52.